Stockscreener 앱 받기
1.84
2.49%
0.03
전일 마감가:
$1.81
열려 있는:
$1.78
하루 거래량:
553.88K
Relative Volume:
0.39
시가총액:
$120.63M
수익:
-
순이익/손실:
$-117.50M
주가수익비율:
-0.7667
EPS:
-2.4
순현금흐름:
$-114.31M
1주 성능:
+9.12%
1개월 성능:
+23.67%
6개월 성능:
-56.04%
1년 성능:
-74.55%
1일 변동 폭
$1.78
$1.95
1주일 범위
$1.6706
$1.95
52주 변동 폭
$1.31
$8.33
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
NKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.85 | 120.63M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.93 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.93 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta (NKTX) Upgraded to Buy: Here's Why - MSN
Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com
American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World
What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan
TD Cowen Keeps Their Buy Rating on Nkarta (NKTX) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.11%
자본화:
|
볼륨(24시간):